热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　花旗发布研报称，海吉亚医疗（06078）管理层预期今年相比去年表现更好，主要由于与手术相关的收入将持续增长，产品均价与毛利率压力可控；随着新的大型医院陆续启用，患者数量将有所增加；进一步节省费用；现金流状况改善，潜在并购交易；不存在与疫情期间核酸检测相关的5800万元人民币的应收账款减值问题。该行降海吉亚医疗今明两年收入预测分别17%及21%，纯利预测降16%及20%，以反映去年业绩突显的销售均价压力。以现金流折现率计，目标价由38港元下调至29港元，但仍维持“买入”评级，认为公司在私营医院领域处于有利位置，有望在业界整合中抢占先机。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.